www.immutep.com Open in urlscan Pro
85.13.133.184  Public Scan

Form analysis
0 forms found in the DOM

Text Content

Sign Up for Updates
Menu
 * About us Open submenu
 * Our Science Open submenu
 * Pipeline Open submenu
 * Investors & Media Open submenu
 * Contacts Open submenu
 * Follow us Open submenu

Close submenuAbout us
 * Company Overview
 * Leadership Team
 * Corporate Governance
 * Partnering
 * Career

Close submenuOur Science
 * Our Science
 * Posters & Publications

Close submenuPipeline
 * Clinical Pipeline
 * Clinical Trials

Close submenuInvestors & Media
 * What's new
 * Press releases
 * ASX Announcements
 * SEC Filings
 * In the News & Media
 * Events
 * Presentations
 * Analyst reports
 * Financial reports
 * FAQ

Close submenuContacts
 * Contact
 * Patient Contact
 * Communication Options

Close submenuFollow us
 * Facebook
 * X
 * LinkediIn
 * Youtube
 * Sign Up for Updates

ASX: -
NASDAQ: -

Skip navigation
 * About us
   * Company Overview
   * Leadership Team
   * Corporate Governance
   * Partnering
   * Career
 * Our Science
   * Our Science
   * Posters & Publications
 * Pipeline
   * Clinical Pipeline
   * Clinical Trials
 * Investors & Media
   * What's new
   * Press releases
   * ASX Announcements
   * SEC Filings
   * In the News & Media
   * Events
   * Presentations
   * Analyst reports
   * Financial reports
   * FAQ
 * Contacts
   * Contact
   * Patient Contact
   * Communication Options
 * Follow us
   * Facebook
   * X
   * LinkediIn
   * Youtube
   * Sign Up for Updates



Unlocking the power of the immune system against cancer and autoimmune disease.





A GLOBAL LEADER IN LAG-3 IMMUNOTHERAPY FOR CANCER AND AUTOIMMUNE DISEASES

Immutep is a clinical-stage biotechnology company at the forefront of developing
novel LAG-3 Immunotherapy for cancer and autoimmune diseases. We are pioneers in
the understanding and advancement of therapeutics related to Lymphocyte
Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in
regulating the immune system.

Our LAG-3 immunotherapies are distinctly designed to harness and strengthen the
power of patients' immune systems to fight cancer and autoimmune disease.


LATEST PRESS RELEASES.

December 17th 2024


IMMUTEP ANNOUNCES INITIAL SAFETY DATA FROM FIRST-IN-HUMAN PHASE I TRIAL
EVALUATING IMP761

December 16th 2024


IMMUTEP AND MONASH UNIVERSITY ANNOUNCE FIRST PUBLICATION DETAILING HOW HUMAN
LAG-3 BINDS TO MHC CLASS II

December 12th 2024


IMMUTEP REPORTS PROMISING NEW DATA IN HEAD AND NECK CANCER AT ESMO
IMMUNO-ONCOLOGY 2024

more


ABOUT US.


OUR SCIENCE.

Utilizing our LAG-3 expertise, we’re focused on safely delivering on
immunotherapy’s promise to drive superior clinical outcomes for patients.


OUR PIPELINE.

We have three clinical-stage & two earlier stage candidates, reflecting our
unique ability to harness the LAG-3 immune checkpoint in multiple ways to
stimulate or suppress the immune system.


INVESTORS & MEDIA.

We are dedicated to leveraging our technology to develop innovative treatment
options for patients and to maximise value to shareholders. Learn more.


Skip navigation
 * Imprint
 * Privacy Policy



We use cookies and other tracking technologies to improve your browsing
experience on our website, to analyze our website traffic, and to understand
where our visitors are coming from. By browsing our website, you consent to our
use of cookies and other tracking technologies. To learn more about cookies view
our

Essential Show details Hide details
Contao HTTPS CSRF Token

Protects against cross-site request forgery attacks.

Retention period: This cookie only lasts for the current browser session.
PHP SESSION ID

Saves the current PHP session.

Retention period: This cookie only lasts for the current browser session.
Google Analytics Show details Hide details
Google Analytics
Provider: Google Ireland Ltd., Gordon House, Barrow Street, Dublin 4, Ireland
Save selection Accept all Deny all
Imprint Privacy Policy
Close menu